Heart failure is a major health problem in the United States and around the world. It affects millions of people and places a heavy burden on families, hospitals, and healthcare systems. When someone has heart failure, it means their heart is not working as well as it should.
The heart’s job is to pump blood around the body, carrying oxygen and nutrients to all organs. When this process does not work properly, people may feel tired, short of breath, and may notice swelling in their legs or body due to fluid buildup.
Many people think heart failure always means the heart is weak. This is true for one common type, where the heart cannot pump strongly enough. However, there is another type that is just as common but less well understood.
In this type, the heart can still pump normally, but it becomes stiff and cannot relax properly between beats. Because of this stiffness, the heart cannot fill with enough blood. This condition is called heart failure with preserved ejection fraction, or HFpEF, and is sometimes described as “stiff heart” failure.
HFpEF is especially common in older adults and people with high blood pressure, diabetes, or obesity. Despite how common it is, doctors still do not have many proven treatments for this condition. This makes it harder to manage and treat compared to the “weak heart” type of heart failure.
A new study from the University of Vermont has raised concerns about a widely used group of medications called beta-blockers. These drugs are commonly prescribed to people with heart problems.
They work by slowing down the heart rate and lowering blood pressure, which can reduce strain on the heart. For patients with weak heart failure, beta-blockers are known to save lives and reduce hospital visits.
However, their role in stiff heart failure is not clear. Because there are limited treatment options for HFpEF, doctors often prescribe beta-blockers based on their success in other types of heart disease. But this new research suggests that this approach may not always be safe.
The researchers examined data from a large clinical study known as the TOPCAT trial. This study included many patients diagnosed with HFpEF. In this group, about 80 percent of patients were taking beta-blockers.
When the researchers analyzed the data, they found something surprising and concerning. Patients who were taking beta-blockers were 74 percent more likely to be hospitalized for heart failure compared to those who were not taking these drugs.
This finding suggests that beta-blockers may not only fail to help people with stiff heart failure, but they could actually make their condition worse. One possible explanation is related to how the heart works in HFpEF.
In this condition, the heart already has difficulty relaxing and filling with blood. Beta-blockers can slow the heart and may increase pressure inside the heart. This can lead to more fluid buildup and worsen symptoms like breathlessness and swelling.
The study highlights an important problem in modern medicine. Treatments that work well for one group of patients may not work the same way for another group. In the case of heart failure, different types of the disease may require very different approaches. Using the same medication for all patients without clear evidence can sometimes lead to unexpected harm.
For patients and their families, this research is a reminder of the importance of asking questions about treatment.
People with HFpEF should talk with their doctors about whether their medications are supported by strong evidence for their specific condition. Medical decisions should always be based on the best available research and tailored to each individual.
The research was led by Dr. Timothy Plante and was published in the journal JAMA Network Open. The authors hope their findings will encourage more studies focused on finding safe and effective treatments for HFpEF. At the moment, this condition remains one of the biggest unmet needs in heart disease care.
As scientists continue to learn more, it is becoming clear that heart failure is not a single disease but a group of related conditions. Understanding these differences is key to improving treatment and helping patients live longer and healthier lives.
If you care about health, please read studies about the benefits of low-dose lithium supplements, and what we know about egg intake and heart disease.
For more health information, please see recent studies about potatoes and high blood pressure, and results showing 6 best breads for people with heart disease.
Copyright © 2026 Knowridge Science Report. All rights reserved.
